Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range

Paris, France and Camberley, UK – 17 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s SNPsig® SARS-CoV-2 polymerase chain reaction (PCR) genotyping portfolio has been included in the NHS England Framework for detecting Variants of Concern (VoC). Novacyt also announces the launch of two

Visit Page

Novacyt to support UNICEF with donation of one million COVID-19 tests

Donation supports testing efforts to help ensure continued access to essential services for children and their families Paris, France and Camberley, UK – 4 May 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT; “Novacyt”), an international clinical diagnostics company, will donate one million COVID-19 polymerase chain reaction (PCR) tests to UNICEF to help contain

Visit Page

R&D and UK operational update

Paris, France and Camberley, UK – 23 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term COVID-19 research and development (R&D) programmes to address rapidly evolving testing demands, particularly as SARS-CoV-2 continues to mutate around the world. Novacyt also provides

Visit Page